LLY240920P980000
- 47.00
- 0.000.00%
Eli Lilly and Co Newsroom
Express News | Eli Lilly and Co: We hope that those who have used cheap weight loss drugs will provide records.
The Best Biotech Plays Outside the GLP-1 Weight-loss Market
Tandem Diabetes Rises as Insulin Pump Cleared for Use in EU With Lilly Insulin
Weight Loss Drug Developer BioAge Seeks up to $602M Valuation in U.S. IPO
Is the Federal Reserve starting an interest rate cut cycle on the cusp of a wave, possibly revealing the outcome of the election in advance?
Taking history as a lesson, in an election year with declining interest rates, the probability of the incumbent president or challenger winning is greater.
Vanda Slips as FDA Rejects Therapy for Stomach Condition
Unmissable investment strategy! The Federal Reserve officially enters a new era of interest rate cuts, these 6 industries have the most profitable potential.
Prepare yourself for the interest rate cut cycle.
Eli Lilly and Company (LLY): Hedge Funds Are Bullish On This Counter Cyclical and Defensive Stock to Invest In
ResMed Slips as Wolfe Downgrades on GLP-1 Threat From Lilly
Sen. Sanders Says Generic Drugmakers Willing to Sell Ozempic for Less Than $100
Weight Loss Drug Pricing Under Fire With Pills on the Horizon
ResMed Stock Is S&P 500's Worst Performer. GLP-1 Drugs Are a Risk. -- Barrons.com
Over a hundred former Republican officials have written an open letter supporting Harris: Trump is not suitable to regain the White House.
① These Republican officials have served in institutions such as the White House, Department of Defense, Department of the Treasury, Department of State, Department of Justice, Department of Homeland Security, and Congress; ② These officials expressed that although there may be policy differences with Harris, compared to the "chaos and unethical behavior" displayed by Trump, these concerns are insignificant.
Express News | Axcelead Drug Discovery Partners: Entered R&D Collaboration With Lilly for Drug Discovery Programs
Unhappy with the high stock price of weight-loss drugs, US senators are pressuring Novo-Nordisk: generic drug prices can be lower than $100/month.
Generic drug companies can sell generic versions of novo-nordisk a/s (NVO.US) diabetes drug Ozempic for less than $100 per month.
Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth
Weight-loss Drug Competition Heats up With Growing Pill Market
Looking Into Eli Lilly's Recent Short Interest
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
Rhythm Pharma Draws Bullish View at JMP on Opportunity in Rare Genetic Obesities